表紙:サイトカイン放出症候群(CRS):疫学予測(2030年)
市場調査レポート
商品コード
948138

サイトカイン放出症候群(CRS):疫学予測(2030年)

Cytokine Release Syndrome (CRS) - Epidemiology Forecast - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.93円
サイトカイン放出症候群(CRS):疫学予測(2030年)
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

サイトカイン放出症候群(CRS)は、感染症や特定の薬剤など様々な要因によって引き起こされる全身性の炎症反応であり、T細胞の過剰活性化を引き起こし、T細胞や他の免疫細胞型によるサイトカインの過分泌を引き起こします。主要7ヶ国(米国、ドイツ、フランス、イタリア、スペイン、英国、日本)においてCAR-T細胞療法後にサイトカイン放出症候群を発症した総件数(2017年)は31件でした。 予測期間中に承認される新規CAR-T細胞治療薬は、既存のYescartaやKymriahなどに比べサイトカイン放出症候群の発生率が低下すると予備結果がでています。

当レポートは、主要7ヶ国のサイトカイン放出症候群(CRS)について調査しており、疾患の概要、治療法、症例や統計などの情報を提供しています。

目次

第1章 主な洞察

第2章 CRSの概要

第3章 疾患の背景と概要

  • イントロダクション
  • 症状
  • 原因
  • 危険因子
  • 病態生理
  • バイオマーカー
  • COVID-19感染患者のCRS
  • 診断

第4章 症例報告

  • 紫斑病を引き起こす重篤なサイトカイン放出症候群
  • 胃癌に対するNivolumab使用後の最初の症例
  • CAR-T細胞療法による子供の発症の治療アプローチ

第5章 疫学と患者人口

  • 主な調査結果
  • 範囲
  • KOLの見解
  • 多発性骨髄腫の治療パラダイム
  • DLBCL治療パラダイム
  • 全治療パラダイム
  • CAR-T細胞療法の予測フロー
  • CRS疫学調査手法
  • 主要7ヶ国でCAR-T細胞療法を受けている血液悪性腫瘍患者の総数
  • 主要7ヶ国のCAR-T細胞療法後にCRSを発症した総患者数

第6章 米国の疫学

  • 前提条件と根拠
  • CAR-T細胞療法を受けているB細胞NHL患者の総数
  • CAR-T細胞療法を受けている急性リンパ芽球性白血病(ALL)患者の総数
  • CAR-T細胞療法を受けている多発性骨髄腫(MM)患者の総数
  • CAR-T細胞療法後にCRSを発症している患者の総数
  • 重症度/等級別のCRSを発症している患者の数

第7章 欧州5ヶ国疫学

  • 前提条件と根拠
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国

第8章 日本の疫学

第9章 付録

  • 参考文献
  • レポート調査手法

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

図表

List of Tables

  • Table 1 Summary of Cytokine Release Syndrome (CRS), Epidemiology and Key Events (2017-2030)
  • Table 2 Clinical risk factors for severe CRS
  • Table 3 Cytokines and Chemokines involved in CRS
  • Table 4 Diagnostic criteria for severe CRS
  • Table 5 Differential diagnoses of CRS-related HLH/MAS
  • Table 6 Published CRS grading systems
  • Table 7 ASTCT CRS Consensus grading
  • Table 8 Total Number of Hematologic malignancies Patients receiving CAR-T Cell Therapies in the 7MM (2017-2030)
  • Table 9 Total Number of Patients develop CRS following CAR-T Cell Therapies in the 7MM (2017-2030)
  • Table 10 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the US (2017-2030)
  • Table 11 Total Number of ALL Patients receiving CAR-T Cell Therapies in the US (2017-2030)
  • Table 12 Total Number of MM Patients receiving CAR-T Cell Therapies in the US (2017-2030)
  • Table 13 Total Number of Patients developing CRS following CAR-T Cell Therapies in the US (2017-2030)
  • Table 14 Number of Patients Developing CRS by Severity/Grade in the US (2017-2030)
  • Table 15 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Germany (2017-2030)
  • Table 16 Total Number of ALL Patients receiving CAR-T Cell Therapies in Germany (2017-2030)
  • Table 17 Total Number of MM Patients receiving CAR-T Cell Therapies in Germany (2017-2030)
  • Table 18 Total Number of Patients developing CRS following CAR-T Cell Therapies in Germany (2017-2030)
  • Table 19 Number of Patients Developing CRS by Severity/Grade in Germany (2017-2030)
  • Table 20 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in France (2017-2030)
  • Table 21 Total Number of ALL Patients receiving CAR-T Cell Therapies in France (2017-2030)
  • Table 22 Total Number of MM Patients receiving CAR-T Cell Therapies in France (2017-2030)
  • Table 23 Total Number of Patients developing CRS following CAR-T Cell Therapies in France (2017-2030)
  • Table 24 Number of Patients Developing CRS by Severity/Grade in France (2017-2030)
  • Table 25 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Italy (2017-2030)
  • Table 26 Total Number of ALL Patients receiving CAR-T Cell Therapies in Italy (2017-2030)
  • Table 27 Total Number of MM Patients receiving CAR-T Cell Therapies in Italy (2017-2030)
  • Table 28 Total Number of Patients developing CRS following CAR-T Cell Therapies in Italy (2017-2030)
  • Table 29 Number of Patients Developing CRS by Severity/Grade in Italy (2017-2030)
  • Table 30 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Spain (2017-2030)
  • Table 31 Total Number of ALL Patients receiving CAR-T Cell Therapies in Spain (2017-2030)
  • Table 32 Total Number of MM Patients receiving CAR-T Cell Therapies in Spain (2017-2030)
  • Table 33 Total Number of Patients developing CRS following CAR-T Cell Therapies in Spain (2017-2030)
  • Table 34 Number of Patients Developing CRS by Severity/Grade in Spain (2017-2030)
  • Table 35 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the UK (2017-2030)
  • Table 36 Total Number of ALL Patients receiving CAR-T Cell Therapies in the UK (2017-2030)
  • Table 37 Total Number of MM Patients receiving CAR-T Cell Therapies in the UK (2017-2030)
  • Table 38 Total Number of Patients developing CRS following CAR-T Cell Therapies in the UK (2017-2030)
  • Table 39 Number of Patients Developing CRS by Severity/Grade in the UK (2017-2030)
  • Table 40 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Japan (2017-2030)
  • Table 41 Total Number of ALL Patients receiving CAR-T Cell Therapies in Japan (2017-2030)
  • Table 42 Total Number of MM Patients receiving CAR-T Cell Therapies in Japan (2017-2030)
  • Table 43 Total Number of Patients developing CRS following CAR-T Cell Therapies in Japan (2017-2030)
  • Table 44 Number of Patients Developing CRS by Severity/Grade in Japan (2017-2030)

List of Figures

  • Figure 1 Pathogenesis and management of CRS
  • Figure 2 Clinical presentation of CRS
  • Figure 3 Causes of CRS
  • Figure 4 Mechanism of CAR T-cell therapy and CRS
  • Figure 5 Pathophysiology of CRS
  • Figure 6 Pathways leading to CRS
  • Figure 7 United States KOL Views
  • Figure 8 Europe KOL Views
  • Figure 9 Total Number of Hematologic malignancies Patients receiving CAR-T Cell Therapies in the 7MM (2017-2030)
  • Figure 10 Total Number of Patients develop CRS following CAR-T Cell Therapies in the 7MM (2017-2030)
  • Figure 11 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the US (2017-2030)
  • Figure 12 Total Number of ALL Patients receiving CAR-T Cell Therapies in the US (2017-2030)
  • Figure 13 Total Number of MM Patients receiving CAR-T Cell Therapies in the US (2017-2030)
  • Figure 14 Total Number of Patients developing CRS following CAR-T Cell Therapies in the US (2017-2030)
  • Figure 15 Number of Patients Developing CRS by Severity/Grade in the US (2017-2030)
  • Figure 16 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Germany (2017-2030)
  • Figure 17 Total Number of ALL Patients receiving CAR-T Cell Therapies in Germany (2017-2030)
  • Figure 18 Total Number of MM Patients receiving CAR-T Cell Therapies in Germany (2017-2030)
  • Figure 19 Total Number of Patients developing CRS following CAR-T Cell Therapies in Germany (2017-2030)
  • Figure 20 Number of Patients Developing CRS by Severity/Grade in Germany (2017-2030)
  • Figure 21 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in France (2017-2030)
  • Figure 22 Total Number of ALL Patients receiving CAR-T Cell Therapies in France (2017-2030)
  • Figure 23 Total Number of MM Patients receiving CAR-T Cell Therapies in France (2017-2030)
  • Figure 24 Total Number of Patients developing CRS following CAR-T Cell Therapies in France (2017-2030)
  • Figure 25 Number of Patients Developing CRS by Severity/Grade in France (2017-2030)
  • Figure 26 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Italy (2017-2030)
  • Figure 27 Total Number of ALL Patients receiving CAR-T Cell Therapies in Italy (2017-2030)
  • Figure 28 Total Number of MM Patients receiving CAR-T Cell Therapies in Italy (2017-2030)
  • Figure 29 Total Number of Patients developing CRS following CAR-T Cell Therapies in Italy (2017-2030)
  • Figure 30 Number of Patients Developing CRS by Severity/Grade in Italy (2017-2030)
  • Figure 31 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Spain (2017-2030)
  • Figure 32 Total Number of ALL Patients receiving CAR-T Cell Therapies in Spain (2017-2030)
  • Figure 33 Total Number of MM Patients receiving CAR-T Cell Therapies in Spain (2017-2030)
  • Figure 34 Total Number of Patients developing CRS following CAR-T Cell Therapies in Spain (2017-2030)
  • Figure 35 Number of Patients Developing CRS by Severity/Grade in Spain (2017-2030)
  • Figure 36 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the UK (2017-2030)
  • Figure 37 Total Number of ALL Patients receiving CAR-T Cell Therapies in the UK (2017-2030)
  • Figure 38 Total Number of MM Patients receiving CAR-T Cell Therapies in the UK (2017-2030)
  • Figure 39 Total Number of Patients developing CRS following CAR-T Cell Therapies in the UK (2017-2030)
  • Figure 40 Number of Patients Developing CRS by Severity/Grade in the UK (2017-2030)
  • Figure 41 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Japan (2017-2030)
  • Figure 42 Total Number of ALL Patients receiving CAR-T Cell Therapies in Japan (2017-2030)
  • Figure 43 Total Number of MM Patients receiving CAR-T Cell Therapies in Japan (2017-2030)
  • Figure 44 Total Number of Patients developing CRS following CAR-T Cell Therapies in Japan (2017-2030)
  • Figure 45 Number of Patients Developing CRS by Severity/Grade in Japan (2017-2030)
  • Figure 46 SWOT analysis of CRS
目次
Product Code: DIEI0981

DelveInsight's 'Cytokine Release Syndrome (CRS)-Epidemiology Forecast-2030' report delivers an in-depth understanding of the Cytokine Release Syndrome (CRS), historical and forecasted epidemiology as well as the Cytokine Release Syndrome trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.

Cytokine Release Syndrome (CRS) Understanding

Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by a variety of factors such as infections and certain drugs causing pathologic over-activation of T cells, leading to hypersecretion of cytokines by T cells and other immune cell types.

The symptoms of CRS typically occur within 30-120 min after the infusion has been initiated, and typically the risk is greater during the first infusion. After CAR T-cell therapy, the onset of CRS symptoms seems to be dependent on the administered dose of the active agent of the proliferation kinetics of adoptively transferred cells and ranges from a few minutes up to 14 days but usually occurs within the first week.

Cytokine Release Syndrome (CRS) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Number of B-cell NHL Patients receiving CART-Therapies, Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CART-Therapies, Total Number of Multiple Myeloma (MM) Patients receiving CART-Therapies, Total Number of Patients developing Cytokine Release Syndrome (CRS) following CART therapies, and Total Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade, scenario of CRS in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Cytokine Release Syndrome (CRS) Detailed Epidemiology Segmentation

  • Total number of patients who develop Cytokine Release Syndrome following CART therapies in the 7MM were 31 in 2017.
  • Total number of Hematologic malignancies (Includes ALL, B-Cell NHL (DLBCL, FL, PMBCL, etc.), and Multiple Myeloma) patients receiving CART-therapies in the 7MM were observed to be 41 in 2017. These cases will increase in the 7MM throughout the study period, i.e., 2017-2030.
  • Both the therapies Yescarta (Axicabtagene ciloleucel, Kite/Gilead) and Kymriah (Tisagenlecleucel, Novartis) were approved in 2017 in the United States and 2018 in EU-5. Kymriah is the only CAR-T cell therapy, which was approved in Japan in 2019
  • Among the European 5 countries, Germany had the highest population of CRS with 13 cases, followed by France and the United Kingdom with 11 cases respectively. On the other hand, Spain had the lowest population of 6 cases in 2018.
  • Based on the severity criteria, CRS has been classified into Grade 1, 2, 3, and 4. Out of the total population of CRS 31 cases in the US, the highest cases were observed in the grade 1 & 2, and lowest cases accounted in grade 4 in 2017.
  • There is no CAR-T therapy which is approved for Multiple Myeloma (MM) patients. According to DelveInsight, there are around 6-8 emerging CAR-T cell therapies which are expected to launch during forecast period for the treatment of MM and patients will experience cytokine release syndrome. As comparison to Yescarta (Axicabtagene ciloleucel, Kite/Gilead) and Kymriah (Tisagenlecleucel, Novartis), new CAR-T cell therapies that are going to be approved in forecast period, will show lower incidence of Cytokine Release Syndrome based on the preliminary results.

Scope of the Report:

  • The report covers the descriptive overview of Cytokine Release Syndrome (CRS), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Cytokine Release Syndrome (CRS).
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Number of B-cell NHL Patients receiving CART-Therapies, Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CART-Therapies, Total Number of Multiple Myeloma (MM) Patients receiving CART-Therapies, Total Number of Patients developing Cytokine Release Syndrome (CRS) following CART therapies, and Total Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade.

Report Highlights:

  • 11-Year Forecast of Cytokine Release Syndrome (CRS)
  • 7MM Coverage
  • Total Number of B-cell NHL Patients receiving CART-Therapies
  • Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CART-Therapies
  • Total Number of Multiple Myeloma (MM) Patients receiving CART-Therapies
  • Total Number of Patients developing Cytokine Release Syndrome (CRS) following CART therapies
  • Total Prevalence of Cytokine Release Syndrome (CRS) based on Risk
  • Total Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade.

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Cytokine Release Syndrome (CRS)?
  • What is the historical Cytokine Release Syndrome (CRS) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Cytokine Release Syndrome (CRS) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Cytokine Release Syndrome (CRS)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Cytokine Release Syndrome (CRS) during the forecast period (2020-2030)?

Reasons to buy:

The Cytokine Release Syndrome (CRS) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Cytokine Release Syndrome (CRS) epidemiology forecast.
  • The Cytokine Release Syndrome (CRS) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Cytokine Release Syndrome (CRS) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1. Key Insights

2. Executive Summary of Cytokine Release Syndrome (CRS)

3. Disease Background and Overview: Cytokine Release Syndrome (CRS)

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Causes
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Biomarkers
  • 3.7. CRS in patients with COVID-19 infection
  • 3.8. Diagnosis
    • 3.8.1. Grading

4. Case Reports

  • 4.1. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: A case report
  • 4.2. The first case of cytokine release syndrome after nivolumab for gastric cancer
  • 4.3. Multimodal therapeutic approach of Cytokine Release Syndrome developing in a child given chimeric antigen receptor-modified T-cell Infusion

5. Epidemiology and Patient Population

  • 5.1. Key Findings
  • 5.2. Scope
  • 5.3. KOL Views
  • 5.4. Multiple Myeloma Treatment Paradigm
  • 5.5. DLBCL Treatment Paradigm
  • 5.6. ALL Treatment Paradigm
  • 5.7. CAR-T Cell Therapies Forecast Flow
  • 5.8. CRS Epidemiology Methodology
  • 5.9. Total Number of Hematologic Malignancies Patients receiving CAR-T Cell Therapies in the 7MM
  • 5.10. Total Number of Patients develop CRS following CAR-T Cell Therapies in the 7MM

6. United States Epidemiology

  • 6.1. Assumptions and Rationale
  • 6.2. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the United States
  • 6.3. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in the United States
  • 6.4. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in the United States
  • 6.5. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in the United States
  • 6.6. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in the United States

7. EU5 Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Germany Epidemiology
    • 7.2.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Germany
    • 7.2.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Germany
    • 7.2.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Germany
    • 7.2.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Germany
    • 7.2.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Germany
  • 7.3. France Epidemiology
    • 7.3.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in France
    • 7.3.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in France
    • 7.3.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in France
    • 7.3.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in France
    • 7.3.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in France
  • 7.4. Italy Epidemiology
    • 7.4.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Italy
    • 7.4.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Italy
    • 7.4.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Italy
    • 7.4.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Italy
    • 7.4.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Italy
  • 7.5. Spain Epidemiology
    • 7.5.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Spain
    • 7.5.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Spain
    • 7.5.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Spain
    • 7.5.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Spain
    • 7.5.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Spain
  • 7.6. United Kingdom Epidemiology
    • 7.6.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the UK
    • 7.6.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in the UK
    • 7.6.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in the UK
    • 7.6.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in the UK
    • 7.6.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in the United Kingdom

8. Japan Epidemiology

  • 8.1. Assumptions and Rationale
  • 8.2. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Japan
  • 8.3. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Japan
  • 8.4. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Japan
  • 8.5. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Japan
  • 8.6. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Japan

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight